1009119-82-7

Usage

Uses

Used in Pharmaceutical Industry:
1,2-Pyrrolidinedicarboxylic acid, 2,2'-[[1,1'-biphenyl]-4,4'-diylbis(2-oxo-2,1-ethanediyl)] bis[1-(1,1-dimethylethyl)] ester, (2S)is used as a pharmaceutical compound for its potential role in drug formulation. The ester group in the compound can be utilized to improve the solubility, stability, and bioavailability of active pharmaceutical ingredients.
Used in Flavor and Fragrance Industry:
In the flavor and fragrance industry, 1,2-Pyrrolidinedicarboxylic acid, 2,2'-[[1,1'-biphenyl]-4,4'-diylbis(2-oxo-2,1-ethanediyl)] bis[1-(1,1-dimethylethyl)] ester, (2S)can be employed as a flavoring agent. The unique structure and chiral center of the compound may contribute to its distinct taste or aroma profile, making it suitable for use in food, beverages, or perfumes.
Used in Solvent Applications:
1,2-Pyrrolidinedicarboxylic acid, 2,2'-[[1,1'-biphenyl]-4,4'-diylbis(2-oxo-2,1-ethanediyl)] bis[1-(1,1-dimethylethyl)] ester, (2S)can also be used as a solvent in various industrial processes. 1,2-Pyrrolidinedicarboxylic acid, 2,2'-[[1,1'-biphenyl]-4,4'-diylbis(2-oxo-2,1-ethanediyl)] bis[1-(1,1-dimethylethyl)] ester, (2S)-'s polarity and solubility properties may make it suitable for dissolving a wide range of substances, facilitating reactions or processes in the chemical, paint, or coating industries.

Upstream product

• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 24860-53-5 1,1’-(biphenyl-4,4’diyl)bis(2-chloroethanone) 
• 99-90-1 para-bromoacetophenone 
• 36934-45-9 1-(4'-acetylbiphenyl-4-yl)-2-bromoethanone 
• 92-52-4 biphenyl 
• 92-91-1 biphenyl-4-acetaldehyde 
• 1228215-09-5 2-{2-[4'-(bromoacetyl)biphenyl-4-yl]-2-oxoethyl} 1-tert-butyl pyrrolidine-1,2-dicarboxylate 
• 787-69-9 4,4'-diacetylbiphenyl 
• 4072-67-7 4,4'-bis(bromoacetyl)biphenyl 

Downstream Products

• 1007882-23-6 methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate 
• 1009119-83-8 methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate hydrochloride 

Relevant academic research and scientific papers

MICRO-ELECTROLYSIS REACTOR FOR ULTRA FAST, OXIDANT FREE, C-C COUPLING REACTION AND SYNTHESIS OF DACLATASVIR ANALOGS THEREOF

The present invention relates to a continuous micro-electro-flow reactor system for ultra-fast, oxidant free, C—C coupling reaction for making symmetrical biaryls and analogs thereof. This invention further relates to the said process for preparation of antiviral drug, daclatasvir of general formula I.

PROCESS FOR THE PREPARATION OF DACLATASVIR DIHYDROCHLORIDE AND ITS INTERMEDIATES

The present invention relates to an improved process for the preparation of Daclatasvir dihydrochloride by using compound salt of formula (VIIc).

PROCESS FOR PREPARATION OF DACLATASVIR AND SALTS

The present invention relates to crystalline daclatasvir dihydrochloride hydrate and process for its preparation.

Anti-hepatitis C Daclatasvir synthesis method

The invention discloses an anti-hepatitis C Daclatasvir synthesis method. The anti-hepatitis C Daclatasvir synthesis method comprises the following steps that 1, 4,4'-di(2-chloracetyl) biphenyl and Boc-L-proline perform condensation to generate ester; 2,

DACLATASVIR FREE BASE AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to daclatasvir free base, processes for its preparation, a process for its conversion into pharmaceutically acceptable salts of daclatasvir. The present invention also relates to a process for the preparation and purification

Preparation method of daclatasvir and its intermediate

The invention discloses a preparation method of daclatasvir and its intermediate. The invention provides a preparation method of a daclatasvir intermediate I. The method includes the step of: in an organic solvent or under a solvent-free condition, subjec

Synthetic method of daclatasvir

The invention discloses a synthetic method of daclatasvir. The method adopts bis(2-bromoacetyl) biphenyl and t-butyloxycarboryl-L-proline as initial raw materials, the initial raw materials are separately synthesized into a midbody N-4, N-3, N-2 and N-1 i

PROCESS FOR THE PREPARATION OF DACLATASVIR

The present disclosure provides a novel process for the preparation of daclatasvir or pharmaceutically acceptable salts thereof using novel intermediates. Formula (I)

Novel method for synthesizing dimethyl dicarbamate dihydrochloride compound

The invention relates to a novel method for synthesizing N,N'[[1,1'-biphenyl]4, 4'-diyl bis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-ethylmethyl)-2-oxo-2,1-ethanediyl]]] dimethyl dicarbamate dihydrochloride. According to the novel method d

Design and synthesis of imidazole N-H substituted amide prodrugs as inhibitors of hepatitis C virus replication

Abstract Twenty-five novel imidazole N-H substituted Daclatasvir (BMS-790052, DCV) analogues (8a-8y) were designed and synthesized as potential prodrugs. Structure modifications were performed in order to improve potency and pharmacokinetic (PK) properties. All target compounds were evaluated in a hepatitis C virus (HCV) genotype 1b replicon, and the 2-oxoethyl acetate substituted compound 8t showed similar anti-HCV activity (EC50 = 0.08 nM) to that of the lead compound Daclatasvir. Moreover, the utility of prodrug 8t was demonstrated through similar exposure of the parent compound when the prodrugs were dosed in vivo. PK studies showed that prodrug 8t was an ideal candidate for a slower and sustained release form of Daclatasvir.